MDT-AP-3043
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 7.5
- sex
- M
- new_clusters
- C4
- umap1_2d
- 2.800621702
- umap2_2d
- 5.332244908
- umap1_3d
- 1.533456762
- umap2_3d
- -1.4024265
- umap3_3d
- -4.306932958
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.500
- E2F_TARGETS+0.460
- MITOTIC_SPINDLE+0.430
- PROTEIN_SECRETION+0.330
- ANDROGEN_RESPONSE+0.310
- TGF_BETA_SIGNALING+0.290
- ALLOGRAFT_REJECTION+0.280
- ANGIOGENESIS+0.270
- UV_RESPONSE_DN+0.240
- INTERFERON_GAMMA_RESPONSE+0.230
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- KRAS_SIGNALING_DN-0.340
- CHOLESTEROL_HOMEOSTASIS-0.270
- MYOGENESIS-0.250
- PANCREAS_BETA_CELLS-0.250
- UV_RESPONSE_UP-0.250
- XENOBIOTIC_METABOLISM-0.240
- COAGULATION-0.230
- FATTY_ACID_METABOLISM-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3329 | Med | Medulloblastoma | 0.833 |
| 2 | TCGA-05-4427-01A-21R-1858-07 | — | cohortA1 | 0.799 |
| 3 | TCGA-BL-A13I-01B-04R-A277-07 | — | — | 0.790 |
| 4 | SJEPD031448_D1.RNA-Seq | EPN | EPN Tumor | 0.775 |
| 5 | TCGA-D8-A1Y0-01A-11R-A14M-07 | — | A | 0.773 |
| 6 | 02aa4891-0590-4a2f-bbd1-da2c88cc1508 | — | — | 0.764 |
| 7 | MDT-AP-3199 | Med | Medulloblastoma | 0.760 |
| 8 | TCGA-E2-A1AZ-01A-11R-A12P-07 | — | D | 0.759 |
| 9 | SRR5088924 | — | — | 0.756 |
| 10 | SRR2016942 | — | — | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |